[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] carbonate
研究用化合物
N-[19-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1,17-dioxo-4,7,10,13-tetraoxa-16-azanonadec-1-yl]-L-valyl-N-[4-[(11aS)-8-[3-[[(11aS)-5,11a-dihydro-7-methoxy-2-(4-methoxyphenyl)-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]propoxy]-5,11a-dihydro-7-methoxy-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl]phenyl]-L-alaninamide
研究用化合物
CL2A-SN-38 是一种复杂的化学化合物，设计用作抗体-药物偶联物研究的连接子-载荷系统。它结合了可裂解连接子部分与细胞毒性载荷 SN-38，用于临床前实验室的靶向递送研究。
内容范围: 本页信息面向化学品识别与工业供应、研发、生产场景，不构成疗效宣称、医疗建议或药品使用指导。
[4-[[(2S)-6-amino-2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetyl]amino]hexanoyl]amino]phenyl]methyl [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] carbonate
CMVRBCDBISKHME-URBSQPMJSA-N
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)[C@H](CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)C=CC8=O)C2=NC9=C1C=C(C=C9)O